Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | BCR | P11274 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.34 |
| ▸ | VCP | P55072 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 2/20 | 0.33 |
| ▸ | FLT4 | P35916 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TEK | Q02763 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733793 | 1.00 | KDR (0.36) | KDRCYP1A2ABL1BCRTRPV1 | |
| SCHEMBL29620994 | 0.88 | KDR (0.37) | KDRCYP1A2ABL1BCRTRPV1 | |
| SCHEMBL22925595 | 0.86 | TRPV1 (0.46) | KDRTRPV1VCPALOX5FLT1 | |
| SCHEMBL28733706 | 0.86 | TRPV1 (0.46) | KDRTRPV1VCPALOX5FLT1 | |
| SCHEMBL24636896 | 0.86 | VCP (0.41) | KDRABL1BCRVCPALOX5 | |
| SCHEMBL29696270 | 0.86 | VCP (0.41) | KDRABL1BCRVCPALOX5 | |
| SCHEMBL22925695 | 0.83 | VCP (0.51) | KDRTRPV1VCPALOX5FLT1 | |
| SCHEMBL29696286 | 0.83 | VCP (0.51) | KDRTRPV1VCPALOX5FLT1 | |
| SCHEMBL28733821 | 0.83 | VCP (0.51) | KDRTRPV1VCPALOX5FLT1 | |
| SCHEMBL28733789 | 0.82 | KDR (0.36) | KDRCYP1A2TRPV1VCPALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | KDR 3951/4885CYP1A2 3598/4885ABL1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.